Gamaryl-VM Tablet SR is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Voglibose (0.2mg), designed to effectively manage type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, improves insulin sensitivity and reduces hepatic glucose production, aiding in better glycemic control. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestines, minimizing postprandial blood sugar spikes. This sustained-release formulation ensures a gradual and prolonged therapeutic effect, enhancing patient compliance by reducing dosing frequency. Gamaryl-VM Tablet SR is typically prescribed when diet, exercise, and monotherapy have not achieved adequate glycemic control. It is important to monitor blood glucose levels regularly and adhere to prescribed lifestyle modifications while on this medication. Common side effects may include gastrointestinal discomfort, hypoglycemia, and rarely, lactic acidosis. Patients with renal or hepatic impairment should use this medication cautiously under medical supervision. Overall, Gamaryl-VM Tablet SR offers a comprehensive approach to managing blood sugar levels by targeting multiple pathophysiological aspects of type 2 diabetes, promoting improved metabolic control and reducing the risk of diabetes-related complications.